Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.38−0.23 (-6.24%)
Close on Nov 17, 2026Market cap $497.53MP/E –Yield –
Aclaris Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Aclaris Therapeutics's price to sales ratio was 73.8× on Nov 11, 2026, against 19.5× a year earlier. Over the last 5 years it ranged from 2.4× to 172.7×, with a median of 19.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 73.8× | +53.1 |
| 2025 | Dec 31, 2025 | 20.7× | +14.2 |
| 2024 | Dec 31, 2024 | 6.5× | +3.1 |
| 2023 | Dec 29, 2023 | 3.5× | −41.2 |
| 2022 | Dec 30, 2022 | 44.7× | −85.5 |
| 2021 | Dec 31, 2021 | 130.2× | +83.8 |
| 2020 | Dec 31, 2020 | 46.3× | +34.8 |
| 2019 | Dec 31, 2019 | 11.5× | −21.6 |
| 2018 | Dec 31, 2018 | 33.1× | – |
See a number that looks wrong?